Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Scientists and legislative activists will meet Tuesday night to discuss the current state of the use of psychedelic substances to treat mental health conditions.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration ...

NEW YORK and BERLIN - atai Life Sciences (NASDAQ: ATAI), a biopharmaceutical company focused on mental health treatments with a current market capitalization of $243 million, announced positive ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

The scientific literature has highlighted the role of inflammation in major depressive disorder (MDD), permeating several states of the disease. In chronic ...